Dietary Intervention in Management and Remission of Ulcerative Colitis: A Systematic Review
DOI:
https://doi.org/10.56570/jimgs.v2i2.136Keywords:
Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Anti-inflammatory diet, Gut microbiome & metabolism, PRISMA systematic reviewAbstract
Ulcerative Colitis (UC), an Inflammatory Bowel Disease (IBD) affecting the colon, is characterized by recurring inflammation in the colon's inner lining. Common symptoms include blood in the stool and diarrhea. Immune responses, gut microbes, and environmental factors contribute to UC's development. Disease relapses impact patients' quality of life. Studies link diet factors like soft drinks, fatty acids, and low fruit/vegetable intake to UC. Promising diets like Specific Carbohydrate Diet (SCD), Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and Polyol (FODMAP), and Inflammatory Bowel Disease-Anti-Inflammatory Diet (IBD-AID) positively affect symptom management. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines, the review searched PubMed and PubMed Central. The screening process identified pertinent articles that were subsequently evaluated for quality before incorporation. Our study has demonstrated that following an anti-inflammatory diet holds the potential to avert subclinical colonic inflammation in UC patients who are in clinical remission. This finding is supported by notable changes in the metabolic and gut microbial compositions among individuals who adhere to the anti-inflammatory diet. The research comprehensively explores the impact of diet on UC, aiming to establish its connection with UC occurrence. It seeks to identify a specific dietary plan for UC individuals and assess its effects on their health. The study also investigates the anti-inflammatory diet's role in UC remission. Evidence shows the anti-inflammatory diet prevents colonic inflammation in UC patients in clinical remission. This finding, accompanied by metabolic and microbial changes, encourages future well-structured trials to assess dietary intervention efficiency in UC remission.References
Keshteli AH, Madsen KL, Dieleman LA. Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions. Nutrients. 2019;11(7):1498. Published 2019 Jun 30. doi:10.3390/nu11071498.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. doi:10.1016/S0140-6736(16)32126-2.
Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019;94(1):155-165. doi: 10.1016/j.mayocp.2018.09.013.
Ananthakrishnan AN. Debate session: So, what causes inflammatory bowel disease? It's all in the environment. J Gastroenterol Hepatol. 2018;33 Suppl 3:24. doi:10.1111/jgh.14429.
Keshteli AH, Valcheva R, Nickurak C, et al. Anti-Inflammatory Diet Prevents Subclinical Colonic Inflammation and Alters Metabolomic Profile of Ulcerative Colitis Patients in Clinical Remission. Nutrients. 2022;14(16):3294. Published 2022 Aug 11. doi:10.3390/nu14163294.
Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11(5):488-496. doi: 10.1097/01.mib.0000159661.55028.56.
Choi CR, Bakir IA, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol. 2017;14(4):218-229. doi:10.1038/nrgastro.2017.1.
Keshteli AH, Madsen KL, Dieleman LA. Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions. Nutrients. 2019;11(7):1498. Published 2019 Jun 30. doi:10.3390/nu11071498.
Malinowski B, Wiciński M, Sokołowska MM, Hill NA, Szambelan M. The Rundown of Dietary Supplements and Their Effects on Inflammatory Bowel Disease-A Review. Nutrients. 2020;12(5):1423. Published 2020 May 14. doi:10.3390/nu12051423.
Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, et al. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2019;2(2):CD012839. Published 2019 Feb 8. doi: 10.1002/14651858.CD012839.pub2.
Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541-1547. doi:10.1111/head.12246.
Chiba M, Nakane K, Tsuji T, et al. Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. Perm J. 2019; 23:18-220. doi:10.7812/TPP/18-220.
Głąbska D, Guzek D, Lech G. Analysis of the Nutrients and Food Products Intake of Polish Males with Ulcerative Colitis in Remission. Nutrients. 2019;11(10):2333. Published 2019 Oct 1. doi:10.3390/nu11102333.
Jian L, Anqi H, Gang L, et al. Food Exclusion Based on IgG Antibodies Alleviates Symptoms in Ulcerative Colitis: A Prospective Study. Inflamm Bowel Dis. 2018;24(9):1918-1925. doi:10.1093/ibd/izy110.
Morton H, Pedley KC, Stewart RJC, Coad J. Inflammatory Bowel Disease: Are Symptoms and Diet Linked? Nutrients. 2020;12(10):2975. Published 2020 Sep 29. doi:10.3390/nu12102975.
Cochrane Methods Bias: Rob 2: A revised Cochrane risk-of-bias tool for randomized trials. [ Jul; 2022]. 2021. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials.
Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS One. 2021;16(2):e0246871. Published 2021 Feb 11. doi: 10.1371/journal.pone.0246871.
Baethge C, Goldbeck-Wood, S. & Mertens, S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 4, 5 (2019). https://doi.org/10.1186/s41073-019-0064-8
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. Published 2021 Mar 29. doi:10.1136/bmj. n71.
Khalili H, Chan SSM, Lochhead P, Ananthakrishnan AN, Hart AR, Chan AT. The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2018;15(9):525-535. doi:10.1038/s41575-018-0022-9.
Keshteli AH, van den Brand FF, Madsen KL, et al. Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. World J Gastroenterol. 2017;23(21):3890-3899. doi:10.3748/wjg. v23.i21.3890.
Mozaffari H, Daneshzad E, Larijani B, Bellissimo N, Azadbakht L. Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies. Eur J Nutr. 2020;59(1):1-17. doi:10.1007/s00394-019-01901-0.
Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218-2227. doi:10.1038/ajg.2010.218.
Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24(8):1415-1422. doi: 10.1016/j.jnutbio.2013.05.001.
Singla V, Pratap Mouli V, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014;8(3):208-214. doi: 10.1016/j.crohns.2013.08.006.
Salehi B, Mishra AP, Nigam M, et al. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines. 2018;6(3):91. Published 2018 Sep 9. doi:10.3390/biomedicines6030091.
Casellas F, Borruel N, Torrejón A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007;25(9):1061-1067. doi:10.1111/j.1365-2036.2007.03288. x.
Parada Venegas D, De la Fuente MK, Landskron G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases [published correction appears in Front Immunol. 2019 Jun 28; 10:1486]. Front Immunol. 2019; 10:277. Published 2019 Mar 11. doi:10.3389/fimmu.2019.00277.
Scaioli E, Sartini A, Bellanova M, et al. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018;16(8):1268-1275.e2. doi: 10.1016/j.cgh.2018.01.036.
Pedersen N, Ankersen DV, Felding M, et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(18):3356-3366. doi:10.3748/wjg. v23.i18.3356.
Triantafillidis JK, Vagianos C, Papalois AE. The role of enteral nutrition in patients with inflammatory bowel disease: current aspects. Biomed Res Int. 2015; 2015:197167. doi:10.1155/2015/197167.
Haskey N, Gibson DL. An Examination of Diet for the Maintenance of Remission in Inflammatory Bowel Disease. Nutrients. 2017;9(3):259. Published 2017 Mar 10. doi:10.3390/nu9030259.
Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15(1):39-49. doi:10.1038/nrgastro.2017.136.
WRIGHT R, TRUELOVE SC. A CONTROLLED THERAPEUTIC TRIAL OF VARIOUS DIETS IN ULCERATIVE COLITIS. Br Med J. 1965;2(5454):138-141. doi:10.1136/bmj.2.5454.138
Candy S, Borok G, Wright JP, Boniface V, Goodman R. The value of an elimination diet in the management of patients with ulcerative colitis. S Afr Med J. 1995;85(11):1176-1179.
